Oragenics, Inc. to Present at Upcoming Conferences in October

Download as PDF

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will present and meet with investors at The MicroCap Conference on October 1, 2018, at 1:00 PM ET as part of Track 1 at The Essex House in New York City. The company will then present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018, at 1:00 PM ET as part of Track 6 in the Madeleine Room at the Sofitel Hotel in New York City.

Interested investors may request a one-on-one meeting at The MicroCap Conference by registering for the meeting at www.microcapconf.com, or at the Ladenburg Thalmann 2018 Healthcare Conference by emailing HealthcareConference@ladenburg.com.

About Oragenics, Inc.

We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries. The collaborations allows Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

For more information about Oragenics, please visit www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

Oragenics, Inc.
Corporate:
Michael Sullivan, 813-286-7900
Chief Financial Officer
msullivan@oragenics.com
or
Investors:
CORE IR
John Marco, 310-819-2948
Managing Director
johnm@coreir.com
or
Media:
CORE IR
Jules Abraham, 917-885-7378
julesa@coreir.com

Source: Oragenics, Inc.

Released September 25, 2018